Literature DB >> 25653431

p53-derived host restriction of HIV-1 replication by protein kinase R-mediated Tat phosphorylation and inactivation.

Cheol-Hee Yoon1, Sang-Yoon Kim1, Se Eun Byeon1, Yideul Jeong1, Jinjoo Lee1, Kwang Pyo Kim2, Jinseu Park3, Yong-Soo Bae4.   

Abstract

UNLABELLED: Tumor suppressor p53 has been suggested to be a host restriction factor against HIV-1 replication, but the detailed molecular mechanism has remained elusive for decades. Here, we demonstrate that p53-mediated HIV-1 suppression is attributed to double-stranded RNA (dsRNA)-dependent protein kinase (PKR)-mediated HIV-1 trans-activator (Tat) phosphorylation and inactivation. p53 silencing significantly enhanced HIV-1 replication in infected cells. Ectopic expression of p53 suppressed Tat activity, which was rescued by PKR silencing. In addition, ectopic expression of PKR abolished Tat activity in p53(-/-) and eIF2α(CA) cells. Finally, we found that HIV-1 infection activates p53, followed by the induction and activation of PKR. PKR directly interacted with HIV-1 Tat and phosphorylates the first exon of Tat exclusively at five Ser/Thr residues (T23, T40, S46, S62, and S68), which inhibits Tat-mediated provirus transcription in three critical steps: (i) phosphorylation near the arginine-rich motif (ARM) inhibits Tat translocation into the nucleus, (ii) accumulation of Tat phosphorylation abolishes Tat-Tat-responsive region (TAR) binding, and (iii) Tat phosphorylation at T23 and/or T40 obliterates the Tat-cyclin T1 interaction. These five Ser/Thr sites on Tat were highly conserved in HIV-1 strains prevalent in Europe and the United States. Taken together, our findings indicate that p53-derived host restriction of HIV-1 replication is likely attributable, at least in part, to a noncanonical p53/PKR/Tat phosphorylation and inactivation pathway in HIV-1 infection and AIDS pathogenesis. IMPORTANCE: HIV-1-mediated disease progression to AIDS lasts for years to decades after primary infection. Host restriction and associated viral latency have been studied for several decades. p53 has been suggested as an important host restriction factor against HIV-1 replication. However, the detailed molecular mechanism is still unclear. In the present study, we found that the p53-mediated HIV-1 restriction is attributed to a p53/PKR/Tat-inactivation pathway. HIV-1 infection activated p53, which subsequently induced PKR expression and activation. PKR directly phosphorylated Tat exclusively at five specific Ser/Thr residues, which was accompanied by significant suppression of HIV-1 replication. Accumulation of Tat phosphorylation at these sites inhibited Tat function by blocking Tat nuclear localization, Tat binding to TAR, and Tat-cyclin T1 interaction. Our findings provide a better understanding of the p53-derived host restriction mechanism against HIV-1 replication in AIDS pathogenesis and may contribute to further research focusing on the investigation of potential therapeutic targets for HIV-1.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25653431      PMCID: PMC4442402          DOI: 10.1128/JVI.03087-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Full peptide synthesis, purification, and characterization of six Tat variants. Differences observed between HIV-1 isolates from Africa and other continents.

Authors:  J M Péloponèse; Y Collette; C Grégoire; C Bailly; D Campèse; E F Meurs; D Olive; E P Loret
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

2.  The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin beta-dependent nuclear localization signals.

Authors:  R Truant; B R Cullen
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.

Authors:  P Wei; M E Garber; S M Fang; W H Fischer; K A Jones
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

4.  The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II.

Authors:  T P Cujec; H Okamoto; K Fujinaga; J Meyer; H Chamberlin; D O Morgan; B M Peterlin
Journal:  Genes Dev       Date:  1997-10-15       Impact factor: 11.361

5.  A novel approach to protein-protein interaction: complex formation between the p53 tumor suppressor and the HIV Tat proteins.

Authors:  F Longo; M A Marchetti; L Castagnoli; P A Battaglia; F Gigliani
Journal:  Biochem Biophys Res Commun       Date:  1995-01-05       Impact factor: 3.575

6.  The Tat protein of human immunodeficiency virus type 1 is a substrate and inhibitor of the interferon-induced, virally activated protein kinase, PKR.

Authors:  S R Brand; R Kobayashi; M B Mathews
Journal:  J Biol Chem       Date:  1997-03-28       Impact factor: 5.157

7.  Footprinting RNA-protein complexes following gel retardation assays: application to the R-17-procoat-RNA and tat--TAR interactions.

Authors:  L Pearson; C B Chen; R P Gaynor; D S Sigman
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

8.  The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein.

Authors:  M E Garber; P Wei; V N KewalRamani; T P Mayall; C H Herrmann; A P Rice; D R Littman; K A Jones
Journal:  Genes Dev       Date:  1998-11-15       Impact factor: 11.361

9.  HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration.

Authors:  Arik Cooper; Mayra García; Constantinos Petrovas; Takuya Yamamoto; Richard A Koup; Gary J Nabel
Journal:  Nature       Date:  2013-06-05       Impact factor: 49.962

10.  Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1.

Authors:  C J Li; C Wang; D J Friedman; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

View more
  17 in total

Review 1.  Genetic variation and function of the HIV-1 Tat protein.

Authors:  Cassandra Spector; Anthony R Mele; Brian Wigdahl; Michael R Nonnemacher
Journal:  Med Microbiol Immunol       Date:  2019-03-05       Impact factor: 3.402

Review 2.  The Role of E3 Ligase Pirh2 in Disease.

Authors:  Alexandra Daks; Olga Fedorova; Sergey Parfenyev; Ivan Nevzorov; Oleg Shuvalov; Nickolai A Barlev
Journal:  Cells       Date:  2022-04-30       Impact factor: 7.666

Review 3.  Long story short: p53 mediates innate immunity.

Authors:  Jessica Miciak; Fred Bunz
Journal:  Biochim Biophys Acta       Date:  2016-03-04

4.  Induction of a Senescence-Like Phenotype in Cultured Human Fetal Microglia During HIV-1 Infection.

Authors:  Natalie C Chen; Andrea T Partridge; Ferit Tuzer; Justin Cohen; Timothy Nacarelli; Sonia Navas-Martín; Christian Sell; Claudio Torres; Julio Martín-García
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-08-10       Impact factor: 6.053

5.  Identification of Aristolactam Derivatives That Act as Inhibitors of Human Immunodeficiency Virus Type 1 Infection and Replication by Targeting Tat-Mediated Viral Transcription.

Authors:  YoungHyun Shin; Chul Min Park; Hong Gi Kim; Dong-Eun Kim; Min Suk Choi; Jeong-Ah Kim; Byeong-Sun Choi; Cheol-Hee Yoon
Journal:  Virol Sin       Date:  2020-08-10       Impact factor: 4.327

6.  High yields and soluble expression of superoxide dismutases in Escherichia coli due to the HIV-1 Tat peptide via increases in mRNA transcription.

Authors:  Yangdong Sun; Qiao Ye; Min Wu; Yonghong Wu; Chenggang Zhang; Weiqun Yan
Journal:  Exp Mol Med       Date:  2016-10-14       Impact factor: 8.718

7.  The impact of p53 on the early stage replication of retrovirus.

Authors:  Michaela Kinnetz; Faris Alghamdi; Michael Racz; Wenwei Hu; Binshan Shi
Journal:  Virol J       Date:  2017-08-09       Impact factor: 4.099

Review 8.  Virological Mechanisms in the Coinfection between HIV and HCV.

Authors:  Maria Carla Liberto; Emilia Zicca; Grazia Pavia; Angela Quirino; Nadia Marascio; Carlo Torti; Alfredo Focà
Journal:  Mediators Inflamm       Date:  2015-10-01       Impact factor: 4.711

9.  Highly activated p53 contributes to selectively increased apoptosis of latently HIV-1 infected cells upon treatment of anticancer drugs.

Authors:  YoungHyun Shin; Hoyong Lim; Byeong-Sun Choi; Kyung-Chang Kim; Chun Kang; Yong-Soo Bae; Cheol-Hee Yoon
Journal:  Virol J       Date:  2016-08-16       Impact factor: 4.099

10.  Inhibition of HIV early replication by the p53 and its downstream gene p21.

Authors:  Binshan Shi; Hamayun J Sharifi; Sara DiGrigoli; Michaela Kinnetz; Katie Mellon; Wenwei Hu; Carlos M C de Noronha
Journal:  Virol J       Date:  2018-03-27       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.